PTGS2 and neoplasm: Consistent with an important role in tumor initiation, seminal epidemiological studies of the COX-2 inhibitor Celecoxib demonstrated striking benefits in colorectal cancer prevention, but at the risk of increased thrombosis and cardiovascular events, leading to the discontinuation of cancer prevention studies (7, 8).